莫努匹韦 T60951

Product Introduction
Bioactivity


英文名: Molnupiravir

描述: Molnupiravir (MK-4482) (EIDD-2801) 是核糖核苷类似物 EIDD-1931 的异丙酯前体药物，具有口服生物利用度。Molnupiravir 可用于 COVID-19 ，季节性和流行性流感的研究，对多种冠状病毒和流感病毒具有广谱的抗病毒活性，例如，SARS-CoV-2，MERS-CoV，SARS-CoV。

体外活性: Molnupiravir (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease[1]. Molnupiravir (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever[2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 45 mg/mL (136.6 mM)


关键字: EIDD 2801 | MK4482 | Molnupiravir | EIDD2801 | MK 4482

相关产品: SARS-CoV-2-IN-61 | SARS-CoV-2-IN-45 | Remdesivir | Azelastine hydrochloride | SARS-CoV-2-IN-42 | 2-Hydroxycinnamic acid | Scutellarein | SARS-CoV-2-IN-51 | MPI60 | Thapsigargin

相关库: Nucleotide Compound Library | Drug Repurposing Compound Library | Approved Drug Library | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compounds Library Max | Anti-Viral Compound Library | Bioactive Compound Library

莫努匹韦 T60951信息由TargetMol中国为您提供，如您想了解更多关于莫努匹韦 T60951报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途